Company
Investor Materials
Lionheart Health is developing a platform that uses programmed bioelectric stimulation to influence the expression and release of proteins associated with regeneration, recovery and healthy aging.
Key Documents
Investor PresentationOctober 2026 · Ver 3.0 · PDF · 24 slides · 8 MBView PDF →Private Placement Memorandum
Offering terms and risk factors for the Rule 506(c) offering. Please read before investing.
Sept 18, 2026 · PDF · 28 pages View PDF
Executive Summary
Two-page company research brief: platform, strategy, financial snapshot, milestones and risks.
Oct 9, 2026 · PDF · 2 pages View PDF
2025 Annual Report
Letter to shareholders, 2025 results and 2026 targets.
PDF · 32 pages View PDF
The investor presentation is updated regularly; this page always links to the current version.
Executive Summary
Core thesis
Lionheart's initial commercial focus combines regenerative aesthetics and healthspan longevity with clinic services, at-home devices and recurring memberships. Bioelectric-enhanced biologics extend the research strategy beyond device-only interventions.
The company's central hypothesis is that selected electrical signals can modulate specific biological pathways rather than deliver a single generic stimulation effect. Proteins of interest include Klotho, follistatin and BDNF, alongside other targets associated with tissue repair, muscle function and brain health. Protocol effects depend on signal parameters, tissue exposure, patient characteristics and treatment context; protein changes must be validated separately from clinical benefit.
Strategic pillars
Regenerative aesthetics
HairCell and SkinStim programs combine bioelectric stimulation with selected light, electromagnetic, serum and PRF modalities. Clinic protocols and home continuity create multiple product and service opportunities.
Healthspan longevity
Klotho-Up integrates lifestyle, exercise, BodStim EMS, targeted stimulation and biomarker measurement. Muscle, brain and immune function are central outcomes of interest.
Bioelectric-enhanced biologics
Research explores stimulation alongside PRF, peptides and, in advanced investigational programs, cells, gene delivery and secretomes. The aim is to improve biological response; incremental benefit requires controlled testing.
Business model
One platform, multiple routes to market
- Clinic
- The Lionheart 240 Stimulus supports a program-based device model.
- At home
- The 240 Portable, Brain Band and BodStim support continuity between visits.
- Recurring
- Memberships, clinician services, software programs, product sales and clinic licensing offer complementary revenue streams.
The investment case depends on converting this breadth into repeat purchases, clinic utilization and durable unit economics.
Leadership
- Howard J. Leonhardt, Executive Chairman & Co-CEO
- Scott Hoots, Co-CEO
- Scott Jordan, CFO
- Dr. Leslie Miller, CMO
- Brian Lasater, CTO
- Dr. Jorge Genovese, VP Bioelectric Research
- Kelsie Leonhardt, Chief NeuroScientist, Manager Research Clinics
Explore the company
Technology →
Bioelectric protein expression, Klotho therapy and Klotho-expressing stem cells, explained.
Therapeutic Pipeline →
54 programs across ten therapeutic areas, by stage of development.
Products & Protocols →
Top 25 product families, eShop offerings and licensee clinic protocols.
Manufacturing Partners →
The OEM and technology partners behind Lionheart devices and equipment.